Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iris Valtingojer

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cells|October 23, 2021
Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative MedicineEvan R Barry, Vladimir Simov, Iris Valtingojer, et al.
Handbook of Experimental Pharmacology|August 23, 2024
Collaborative Innovations in Childhood Cancer TherapiesIris Valtingojer, Sasha Lièvre, Philippe Bordes, et al.
BMC Cancer|June 10, 2022
YAP1 is essential for malignant mesothelioma tumor maintenanceLoreley Calvet, Odette Dos-Santos, Emmanuel Spanakis, et al.
Pharmaceuticals (Basel, Switzerland)|April 28, 2023
TEAD Inhibitors Sensitize KRAS<sup>G12C</sup> Inhibitors via Dual Cell Cycle Arrest in KRAS<sup>G12C</sup>-Mutant NSCLCSalvina Laura Tammaccaro, Philippe Prigent, Jean-Christophe Le Bail, et al.
Iscience|January 27, 2025
Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patientsBenoit Schmauch, Vincent Cabeli, Omar Darwiche Domingues, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cells|October 23, 2021
Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative MedicineEvan R Barry, Vladimir Simov, Iris Valtingojer, et al.
Handbook of Experimental Pharmacology|August 23, 2024
Collaborative Innovations in Childhood Cancer TherapiesIris Valtingojer, Sasha Lièvre, Philippe Bordes, et al.
BMC Cancer|June 10, 2022
YAP1 is essential for malignant mesothelioma tumor maintenanceLoreley Calvet, Odette Dos-Santos, Emmanuel Spanakis, et al.
Pharmaceuticals (Basel, Switzerland)|April 28, 2023
TEAD Inhibitors Sensitize KRAS<sup>G12C</sup> Inhibitors via Dual Cell Cycle Arrest in KRAS<sup>G12C</sup>-Mutant NSCLCSalvina Laura Tammaccaro, Philippe Prigent, Jean-Christophe Le Bail, et al.
Iscience|January 27, 2025
Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patientsBenoit Schmauch, Vincent Cabeli, Omar Darwiche Domingues, et al.
Pageof 1